This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around ...

Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.

Pfizer Inc. is a global biopharmaceutical leader with a diversified product portfolio and significant scale, supported by ...

Pfizer's stock has been struggling for multiple years, and even a low valuation hasn't made it an enticing option for many investors.

Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...

Over the past decade, pharmaceutical maker Pfizer ( PFE -0.53%) has severely lagged the market. Dividends reinvested aside, ...

After its best day in nearly four years Tuesday, Pfizer stock gave an encore performance. Shares of the drugmaker closed u ...

Pfizer Inc. remains attractive with strong fundamentals, cost control, an expanding market, and new drugs. Click here to read ...

Pfizer, Inc. CEO Albert Bourla said on Tuesday that the U.S. pharmaceutical industry should work more collaboratively with ...

The trial tested the kinase inhibitor TUKYSA with first-line combination therapy for patients with human epidermal growth ...

Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior day's close.

Pfizer is getting its hands on a promising weight management candidate. The company's recent deal with the U.S. government eliminates a major risk. The stock's valuation looks attractive right now.